![Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3 -Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4 -yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects | Journal of Medicinal ... Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3 -Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4 -yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects | Journal of Medicinal ...](https://pubs.acs.org/cms/10.1021/acs.jmedchem.6b00544/asset/images/large/jm-2016-005448_0019.jpeg)
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3 -Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4 -yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects | Journal of Medicinal ...
Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3 -yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of ...
![Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled ... Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled ...](https://www.thelancet.com/cms/attachment/ed1e9eda-de38-45e8-a3a1-5a360c11286b/gr1.jpg)
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled ...
American Journal of Sociology, Vol-31, Issue no.-1, 2, 3, 4, 5, 6 : Free Download, Borrow, and Streaming : Internet Archive
![Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics | Nature Communications Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-28776-w/MediaObjects/41467_2022_28776_Fig1_HTML.png)